GleamWall
中文EN

ALZN Alzamend Neuro, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1677077 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-45.7%
TTM EPS YoY-72.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-163.2%
ROA-122.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets32.1%
Debt / equity0.00x
Current ratio—
Interest coverage-1,480.55x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-30.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-07-312026Q4*2026-04-302026Q32026-01-312026Q22025-10-312026Q12025-07-312025Q4*2025-04-302024Q32025-01-312024Q22024-10-31
Income statement
Revenue————————
R&D expense$1.09M$434,006$1.28M$176,283$1.74M$450,157$447,111$311,088
SG&A expense$1.94M$2.44M$919,025$821,826$959,334$688,779$590,304$1.05M
Operating income-$3.03M-$2.87M-$2.20M-$998,109-$2.70M-$1.14M-$1.04M-$1.36M
Interest expense$2,005$150$1,337$2,649$2,483$509$2,019$3,495
Net income-$3.03M-$2.87M-$2.20M-$1.00M-$2.70M-$1.14M-$1.04M-$1.36M
EBITDA-$3.00M-$2.84M-$2.17M-$970,424-$2.67M-$1.13M-$1.02M-$1.35M
EPS (basic)-0.68—-0.58-0.30-1.28—-1.75-3.61
EPS (diluted)-0.68—-0.58-0.30-1.28—-1.75-3.61
Weighted avg. shares (diluted)4.48M—3.80M3.38M2.11M—611,978392,411
Balance sheet
Cash & equivalents$7.59M$710,689$2.71M$4.45M$5.62M$3.95M$3.36M$4.09M
Current assets$8.25M$1.76M$3.70M$4.72M$5.93M$4.18M$3.95M$4.77M
PP&E, net$287,181$314,866$342,551$370,236$397,921$425,606$228,291$240,976
Total assets$8.54M$2.08M$4.04M$5.09M$6.33M$4.60M$4.18M$5.01M
Total liabilities$2.74M$1.35M$1.86M$717,488$983,311$634,761$725,851$1.25M
Shareholders' equity$5.80M$733,211$2.20M$4.37M$5.34M$3.97M$3.45M$3.75M
Shares outstanding4.83M4.26M3.80M3.80M3.14M778,7335.80M5.23M
Cash flow statement
Operating cash flow-$1.14M-$2.80M-$1.74M-$1.17M-$2.36M-$688,705-$1.42M-$3.40M
Investing cash flow—————-$210,000$0$0
Financing cash flow$8.02M$794,844$0$0$4.04M$1.49M$688,700$6.30M
Depreciation & amortization$27,685$27,685$27,685$27,685$27,685$12,685$12,685$12,685
Stock-based compensation$77,199$623,811$9,300$31,514$42,902$81,277$81,277$81,277

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.